Clinical Trials Logo

Invasive Candidiasis clinical trials

View clinical trials related to Invasive Candidiasis.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT05763251 Recruiting - Clinical trials for Invasive Candidiasis

Comparison of Uncomplicated Candidemia Therapy Duration in Children

COUNT
Start date: September 8, 2023
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to compare antifungal therapy duration in pediatric uncomplicated candidemia. The specific aims are: - Compare the desirability of outcome ranking in children with uncomplicated candidemia randomized to 7 additional days of antifungal therapy (standard-course) versus no additional antifungal therapy (short-course) after already receiving 7 days of echinocandin therapy. - Compare the 14-day desirability of outcome measure for subjects with a negative and those with a positive T2Candida® biomarker at day 7 of therapy within randomized groups. Participants meeting eligibility criteria will be approached and consented between day 5 and 7 of primary systemic antifungal therapy. On day 7 of primary systemic antifungal therapy, inclusion and exclusion criteria will again be reviewed for consented patients and those still eligible will be randomized 1:1 to the two study arms. Researchers will compare no additional antifungal therapy (short-course) versus 7 additional days of systemic antifungal therapy (standard-course) in pediatric patients with uncomplicated candidemia who have already received 7 days of primary systemic antifungal therapy to see if shorter durations are as effective as longer durations in treating uncomplicated candidemia.

NCT ID: NCT04368559 Recruiting - Fungal Infection Clinical Trials

Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation

ReSPECT
Start date: May 11, 2020
Phase: Phase 3
Study type: Interventional

The purpose of this pivotal study is to determine if intravenous Rezafungin is efficacious and safe in the prevention of invasive fungal diseases when compared to the standard antimicrobial regimen.

NCT ID: NCT03538912 Recruiting - Clinical trials for Invasive Candidiasis

Early Discontinuation of Empirical Antifungal Therapy and Biomarkers

SEAT
Start date: June 6, 2018
Phase: N/A
Study type: Interventional

Empirical antifungal therapy (EAT) is frequently prescribed to septic critically ill patients with risk factors for invasive Candida infections (ICI). However, among patients without subsequent proven ICI, antifungal discontinuation is rarely performed, resulting in unnecessary antifungal overuse. The investigators postulate that the use of fungal biomarkers could increase the percentage of early discontinuation of EAT among critically ill patients suspected of ICI, as compared with a standard strategy, without negative impact on day 28-mortality. To test this hypothesis, the investigators designed a randomized controlled open-label parallel-group study.

NCT ID: NCT01438216 Recruiting - Candidemia Clinical Trials

Anidulafungin Pharmacokinetics in Intensive Care Unit Patients

ANICK
Start date: September 2011
Phase: N/A
Study type: Observational

The purpose of this study is to determine the pharmacokinetics of anidulafungin in intensive care patients.